Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
By Dr. Matthew Watson
SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that company management will participate in a fireside chat at the annual SVB Securities Global Biopharma Conference, which is being held in a virtual format February 14-16, 2023.
Follow this link:
Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
Related Post
- Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference - February 20th, 2025
- NAYA Biosciences Announces Nomination of New Board Members - February 20th, 2025
- Intrommune Therapeutics Announces Publication of OMEGA Study in Peanut Allergic Adults in Annals of Allergy, Asthma & Immunology - February 20th, 2025
- OrphAI Therapeutics Announces Appointment of Dr. Aaron Waxman to Board of Directors - February 20th, 2025
- Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate - February 20th, 2025
- Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers - February 20th, 2025
- NurExone Biologic Recognized as a 2025 TSX Venture 50™ Top Performing Stock - February 20th, 2025
- Better Choice Company Adjourns Special Meeting of Stockholders to March 21, 2025 - February 20th, 2025
- COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing - February 20th, 2025
- Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025 - February 20th, 2025
- GRI Bio Announces Reverse Stock Split - February 20th, 2025
- PacBio to Participate in TD Cowen's 45th Annual Health Care Conference - February 20th, 2025
- ANI Pharmaceuticals to Present at Raymond James’ Institutional Investors and Leerink Partners Global Healthcare Conferences in March - February 20th, 2025
- Intelligent Bio Solutions Inc. Announces Proposed Public Offering of Common Stock - February 20th, 2025
- Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025 - February 20th, 2025
- Zealand Pharma Announces Financial Results for the Full Year 2024 - February 20th, 2025
- argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025 - February 20th, 2025
- EG 427 raises €27 million in successful Series B co-led by Andera Partners and Bpifrance to finance on-going clinical study and platform... - February 20th, 2025
- Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN - February 20th, 2025
- Citryll Demonstrates a Broader Therapeutic Potential for CIT-013 in the Treatment of Inflammatory Disorders - February 20th, 2025
- Grace Therapeutics Announces Private Placement Financing of up to $30 Million - February 11th, 2025
- IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer - February 11th, 2025
- Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience - February 11th, 2025
- Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis - February 11th, 2025
- Intelligent Bio Solutions Releases Shareholder Letter Detailing 2024 Growth and 2025 U.S. Expansion Strategy - February 11th, 2025
- Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial - February 11th, 2025
- BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology /... - February 11th, 2025
- Capricor Therapeutics to Participate in Upcoming Investor Conferences - February 11th, 2025
- Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis - February 11th, 2025
- Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting - February 11th, 2025
- Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory... - February 11th, 2025
- Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol - February 11th, 2025
- Revolo to Present at the 2025 AAAAI / WAO Joint Congress - February 11th, 2025
- Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update - February 11th, 2025
- Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update - February 11th, 2025
- Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - February 11th, 2025
- Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation - February 11th, 2025
- LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement - February 11th, 2025
- Novonesis to acquire dsm-firmenich’s share of the Feed Enzyme Alliance - February 11th, 2025
- Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront - February 11th, 2025
- Rakovina Therapeutics Announces Listing on Frankfurt Stock Exchange - January 31st, 2025
- Aclaris Therapeutics Announces Formation of New Scientific Advisory Board - January 31st, 2025
- PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025 - January 31st, 2025
- Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference - January 31st, 2025
- Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference - January 31st, 2025
- Avid Stockholders Approve Transaction with GHO and Ampersand - January 31st, 2025
- Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025 - January 31st, 2025
- Portage Biotech Announces Completion of $2.15 Million Private Financing - January 31st, 2025
- Diag-Nose.io, Graduate of Stanford EENT Innovation, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision... - January 31st, 2025
- Diag-Nose.io Opens Houston Office following oversubscribed $2M Seed Round to Measure Respiratory Treatment Success Using Proteomics & AI - January 31st, 2025
- Diag-Nose.io Expands to Bethlehem, PA, Following Oversubscribed $2M Seed Round Funding to Revolutionize Respiratory Diagnostics - January 31st, 2025
- Diag-Nose.io, Graduate of CDL-Seattle, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision Medicine - January 31st, 2025
- Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform - January 31st, 2025
- BioSyent Declares First Quarter 2025 Dividend - January 31st, 2025
- Tarsus to Participate in Upcoming Investor Conferences - January 31st, 2025
- Ryoncil® Commercial Launch Update and Product Pipeline - January 31st, 2025
- Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024 - January 31st, 2025
- Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024 - January 31st, 2025
- Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for... - January 31st, 2025
- Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provides General Business Update - January 31st, 2025
- Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma - January 22nd, 2025
- Nacuity Pharmaceuticals Granted U.S. FDA Fast Track Designation for NPI-001 (N-acetylcysteine amide) Tablets for the Treatment of Retinitis Pigmentosa - January 22nd, 2025
- Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology - January 22nd, 2025
- Welcoming Victor Bornsztejn as Senior Vice President of Commercial - January 22nd, 2025
- Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization... - January 22nd, 2025
- Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas - January 22nd, 2025
- Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31,... - January 22nd, 2025
- RS BioTherapeutics Announces Positive Anti-Inflammatory and Anti-Fibrotic Effects of Lead Compound in Human Lung Tissue - January 22nd, 2025
- Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1) - January 22nd, 2025
- Pharming Group to convene Extraordinary General Meeting of Shareholders - January 22nd, 2025
- BioAdaptives Announces FINRA Approval of a Dividend for Common Stock Shareholders - January 22nd, 2025
- Sanara MedTech Inc. Expands Executive Leadership Team with New Appointments - January 22nd, 2025
- Sanara MedTech Inc. Announces Exclusive License and Distribution Agreement with, and Minority Investment in, Biomimetic Innovations Ltd - January 22nd, 2025
- Sanara MedTech Inc. Reports Unaudited Preliminary Results for the Fourth Quarter and Full Year 2024 - January 22nd, 2025
- NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director - January 22nd, 2025
- Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO... - January 22nd, 2025
- Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in... - January 22nd, 2025
- Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible... - January 22nd, 2025
- ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI - January 22nd, 2025
- Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care - January 22nd, 2025
Global News Feed
Comments Off on Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference |
February 12th, 2023
This author published 6052 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research